A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when …
DH Yoo, P Hrycaj, P Miranda, E Ramiterre… - Annals of the …, 2013 - ard.bmj.com
Objectives To compare the efficacy and safety of innovator infliximab (INX) and CT-P13, an
INX biosimilar, in active rheumatoid arthritis patients with inadequate response to …
INX biosimilar, in active rheumatoid arthritis patients with inadequate response to …
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in …
…, MJ Lim, YA Lee, SJ Lee, HU Kim, DH Yoo… - Annals of the …, 2013 - ard.bmj.com
… Dae Hyun Yoo12, … Dae Hyun Yoo Pawel Hrycaj Pedro Miranda Edgar Ramiterre Mariusz
Piotrowski Sergii Shevchuk Volodymyr Kovalenko Nenad Prodanovic Mauricio Abello-Banfi …
Piotrowski Sergii Shevchuk Volodymyr Kovalenko Nenad Prodanovic Mauricio Abello-Banfi …
Study of thermal conductivity of nanofluids for the application of heat transfer fluids
DH Yoo, KS Hong, HS Yang - Thermochimica Acta, 2007 - Elsevier
TiO 2 , Al 2 O 3 , Fe, and WO 3 nanofluids are prepared in a two-step procedure by dispersing
nanoparticles in a basefluid. Since nanoparticles form clusters in fluids, a cell disrupter …
nanoparticles in a basefluid. Since nanoparticles form clusters in fluids, a cell disrupter …
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a …
…, YM Kang, SR Kwon, SH Lee, SS Lee, DH Yoo… - The Lancet, 2017 - thelancet.com
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative …
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative …
Animal-assisted and pet-robot interventions for ameliorating behavioral and psychological symptoms of dementia: a systematic review and meta-analysis
Patients with dementia suffer from psychological symptoms such as depression, agitation,
and aggression. One purpose of dementia intervention is to manage patients’ inappropriate …
and aggression. One purpose of dementia intervention is to manage patients’ inappropriate …
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and …
DH Yoo, N Prodanovic, J Jaworski, P Miranda… - Annals of the …, 2017 - ard.bmj.com
Objectives To assess the efficacy and safety of switching from the infliximab reference
product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in …
product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in …
A novel non-intrusive eye gaze estimation using cross-ratio under large head motion
Eye gaze estimation systems calculate the direction of human eye gaze. Numerous accurate
eye gaze estimation systems considering a user’s head movement have been reported. …
eye gaze estimation systems considering a user’s head movement have been reported. …
Influence of essential oil components on growth performance and the functional activity of the pancreas and small intestine in broiler chickens
…, SY Kang, DH Yoo, DS Nam, DH Kim… - … Journal of Animal …, 2004 - koreascience.kr
To investigate the efficacy of alternatives to antibiotics, the present study was conducted to
compare the effects of antibiotic, lactic acid, a blend of commercial essential oils (EOs) and …
compare the effects of antibiotic, lactic acid, a blend of commercial essential oils (EOs) and …
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the …
W Park, DH Yoo, P Miranda, M Brzosko… - Annals of the …, 2017 - ard.bmj.com
Objectives To investigate the efficacy and safety of switching from infliximab reference
product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing …
product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing …
Cytokine balance in kidney tissue from lupus nephritis patients
…, GW Song, SS Jung, T Lee, MH Park, DH Yoo - …, 2003 - academic.oup.com
Objective. To identify the balance of Th1/Th2 cytokine expression in the kidney and evaluate
the difference in cytokine balance between patients with lupus nephritis WHO classes IV …
the difference in cytokine balance between patients with lupus nephritis WHO classes IV …
